drugset / Trial / NCT05960565

Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

NCT05960565

Phase 2 Terminated 9 enrolled St. Olavs Hospital
RandomizedCrossoverOpen-labelTreatment

Summary

The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.

Timeline

Start
2023-12-22
Primary completion
2023-12-22
Completion
2023-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon Peptide Subcutaneous